|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.
|
31572671 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
When we compared mRNA expression levels with the different histological ADC subtypes we found a significant higher expression of VEGF in papillary and solid than in other subtypes (p = 0.008).
|
31044389 |
2019 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In case of both the squamous cell carcinoma and the adenocarcinoma groups, plasma levels of M-CSF and VEGF were higher compared to the control group.
|
31035945 |
2019 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Adenocarcinomas showed significantly higher staining scores of both VEGF and αSMA than squamous cell carcinomas did.
|
29970531 |
2018 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The multivariable analysis confirmed that patients with higher VEGF mRNA levels, as well as with adenocarcinoma and advanced stages, were independent predictors of a poorer survival.
|
29025597 |
2017 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PPARgamma down-regulation and VEGF-A up-regulation are characteristic to both AC and SCC.
|
27876017 |
2016 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
When the survival outcomes were analyzed based on VEGF +405G/C SNPs, however, there was no relationship between VEGF SNPs and overall survival in patients with both IPMNs and pancreatic ductal adenocarcinomas.
|
25875799 |
2015 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The immunohistochemical expression of metabolism-related proteins (MCT1, MCT4, CD147, GLUT1 and CAIX) as well as VEGF family members (VEGF-A, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2 and VEGFR-3) was assessed in a series of 232 cervical adenocarcinomas.
|
26525902 |
2015 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Especially, VEGFA over-expression was an independent prognostic factor in adenocarcinoma (ADC) (HR=1.775, 95%CI: 1.384-2.275) and SCC (HR=2.919, 95%CI: 2.060-4.137).
|
25773840 |
2015 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High expression of VEGF was found in 70% of adenocarcinoma tissues versus 25% in normal tissues (P < 0.05).
|
26782587 |
2015 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
It is not clear whether K-ras mutated adenocarcinomas are sensitive to anti-angiogenic therapy with monoclonal antibodies (mAbs) that target vascular endothelial growth factor (VEGF).
|
25484066 |
2014 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry was used to evaluate epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF-D, VEGF receptor (VEGFR)-2, VEGFR-3, transforming growth factor (TGF)-α, TGF-β1, and TGF-β-RII in tissue microarrays of adenocarcinoma, dysplasia, metaplasia, and gastritis.
|
23030255 |
2013 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Of these, survival was best predicted by CDK1 (p<1E-16), CD24 (p<1E-16) and CADM1 (p = 7E-12) in adenocarcinomas and by CCNE1 (p = 2.3E-09) and VEGF (p = 3.3E-10) in all NSCLC patients.
|
24367507 |
2013 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Peripheral blood CD56(+)CD16(-) NK cells from patients with the squamous cell carcinoma (SCC) subtype showed higher VEGF and PlGF production compared to those from patients with adenocarcinoma (AdC) and controls.
|
23441128 |
2013 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, solid adenocarcinomas showed higher levels of vascular endothelial growth factor using quantitative real-time polymerase chain reaction in the tumor tissue samples than in the nonsolid adenocarcinomas (p = 0.005).
|
22198428 |
2012 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Fresh tissue samples from 37 patients with colorectal adenocarcinomas were analyzed for MAGE and SSX mRNA by reverse transcription-polymerase chain reaction (RT-PCR) and their paraffin-embedded tissues were used for immunohistochemistry for cyclooxygenase 2 (COX2), vascular endothelial growth factor (VEGF), and survivin.
|
22287745 |
2012 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry and fluorescence in situ hybridization (FISH) were used to evaluate the amplification and expression of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF-D, VEGF receptor (VEGFR)-2, VEGFR-3, transforming growth factor (TGF)-β1, and insulin-like growth factor-1 receptor (IGF-1R) in a tissue microarray of 292 colorectal adenocarcinomas.
|
21635552 |
2011 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Pathology samples of human lung adenocarcinomas revealed correlations between EGR-1/HIF-1alpha and VEGF-A expressions and relative elevation of EGR-1 and VEGF-A expression in mutant K-RAS- or EGFR-carrying adenocarcinomas.
|
20489156 |
2010 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VEGF-A expression showed a correlation to histological type with increased expression in adenocarcinomas as compared to squamous cell carcinomas.
|
19324448 |
2009 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese.
|
18414651 |
2008 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
VEGF T-1498C polymorphism is also a candidate marker predictive of poorly-differentiated colorectal adenocarcinomas, but further investigations with a large number of patients should be addressed to draw a conclusion.
|
18414651 |
2008 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
|
18780893 |
2008 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.
|
18450321 |
2008 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, MVD was increased in Ang-2- and VEGF-expressing adenocarcinoma tissues compared to the Ang-2- and VEGF-negative tissues, respectively (p < 0.01).
|
17785951 |
2007 |